Swiss biopharmaceutical company AC Immune has announced it has been awarded a $4 million (approximately £3.2 million) grant to support the extension of a crucial clinical trial for its Parkinson's disease drug candidate, ACI-7104. The funding will enable the firm to prolong the observation period for participants in the ongoing Phase 2 clinical trial, which is evaluating the efficacy and safety of the small molecule inhibitor.
ACI-7104 is designed to target alpha-synuclein, a protein that misfolds and aggregates in the brains of individuals with Parkinson's disease, forming Lewy bodies. These aggregations are believed to play a significant role in the neurodegeneration characteristic of the condition. By inhibiting the aggregation of alpha-synuclein, AC Immune hopes to slow or even halt the progression of Parkinson's, a devastating neurological disorder for which there is currently no cure.
The extension of the Phase 2 trial is a vital step in gathering more comprehensive data on the long-term effects and potential benefits of ACI-7104. Longer observation periods allow researchers to better understand the drug's impact on disease progression, patient symptoms, and overall quality of life. This additional data will be crucial for informing subsequent stages of drug development and potential regulatory submissions.
Parkinson's disease affects approximately 145,000 people in the United Kingdom, according to Parkinson's UK, and this number is projected to rise. The condition is characterised by a range of motor symptoms, including tremors, rigidity, and bradykinesia (slowness of movement), as well as non-motor symptoms such as sleep disturbances, depression, and cognitive impairment. Current treatments primarily focus on managing symptoms, rather than addressing the underlying causes or slowing disease progression.
The grant underscores the significant global effort to find effective treatments for neurodegenerative diseases. While AC Immune is a Swiss-based company, advancements in medical research often have international implications, potentially offering hope to patients worldwide, including those in the UK. The funding source, a foundation dedicated to Parkinson's research, highlights the collaborative nature of scientific discovery and the shared objective of combating this debilitating illness.